H5N1 News and Research

Latest H5N1 News and Research

NanoViricides acquires light industrial building for laboratory facilities and cGMP production

NanoViricides, Inc. announced that Inno-Haven LLC has completed acquisition of a light industrial building. The Company anticipates that it will be leasing a portion of this space, in the near future, for laboratory facilities and cGMP production of its nanoviricides® drug candidates against various viral diseases.

19 Sep 2011

Something like 'Contagion' could happen for influenza

In the new movie "Contagion," fictional health experts scramble to get ahead of a flu-like pandemic as a drug-resistant virus quickly spreads, killing millions of people within days after they contract the illness.

15 Sep 2011

Nexera to submit amended claims for FDA 510(k) clearance of SpectraShield 9500 Surgical N95 Respirator

Nexera Medical, Inc., today announced plans to submit to the U.S. Food and Drug Administration amended antimicrobial claims for its current 510(k) clearance for the SpectraShield 9500 Surgical N95 Respirator with embedded antimicrobial technology. The expanded antimicrobial claims will be supported by test data on the inactivation performance of certain strains of viruses.

8 Sep 2011

'No evidence' mutant bird flu virus poses increased risk to humans, WHO and FAO say

After the U.N. Food and Agriculture Organization (FAO) "last week voiced concern about the appearance in Vietnam and China of" a mutant strain of the H5N1 bird flu virus, the WHO and FAO on Monday "said in a joint statement issued in response to questions from Agence France-Presse" that "there is no evidence to suggest yet that this new virus strain will have any increased risk to human health," the news agency reports.

7 Sep 2011

NanoViricides selects NV-INF-1 anti-influenza drug for FDA submission

NanoViricides, Inc. announced today that it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide anti-influenza therapeutics program.

6 Sep 2011

FAO warns mutant form of H5N1 bird flu poses threat to Asia

"The U.N. Food and Agriculture Organization (FAO) on Monday warned about a new mutant strain of the deadly bird flu H5N1 virus in China and Vietnam, saying there could be a 'major resurgence' of the disease," Agence France-Presse reports.

30 Aug 2011

Bird flu on the rise again

Avian or bird flu is showing signs of a resurgence, while a mutant strain – that cannot be prevented by vaccination - could be spreading in Asia, the United Nations has warned. This mutant strain appeared in Vietnam and China and its risk to humans cannot be predicted, veterinary officials said.

30 Aug 2011

World must invest equally in bird flu prevention and response

The "reports during the past two weeks of two recent infections and another death" from H5N1 (avian) influenza "raised little concern except among public health officials," Robert Gatter, co-director of the Center for Health Law Studies and professor of law at Saint Louis University, writes in an Atlanta Journal-Constitution opinion piece, adding that "the fact that bird flu in developing nations receives little public attention reveals that the world has become complacent about this threat."

18 Aug 2011

CEL-SCI receives Chinese patent for Multikine cancer drug

CEL-SCI Corporation today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine.

18 Aug 2011

Sinovac second quarter sales increase 52.5% to $15.7 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2011.

12 Aug 2011

NanoViricides to apply 'lead optimization technology' to anti-HIV candidate

NanoViricides, Inc. recently reported on its completed animal study that compared its lead anti-HIV candidate HIVCide™, to a HAART (highly active anti retroviral therapy) triple drug cocktail. The cocktail used therein is based on an anti-HIV therapeutic protocol in current practice. The Company has received numerous inquiries for simplified explanation of the results.

3 Aug 2011

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.

25 Jul 2011

CEL-SCI expands licensing agreement with Teva for Multikine cancer drug

CEL-SCI Corporation announced today that it has expanded the licensing agreement with Teva Pharmaceutical Industries Ltd. for its cancer drug Multikine.

20 Jul 2011

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

14 Jul 2011

Positive final results from Medicago's H5N1 Avian Influenza VLP vaccine Phase II trial

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

30 Jun 2011

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

CEL-SCI Corporation announced today that its partner Teva Pharmaceuticals, a leading global pharmaceutical company, has concluded the Site Initiation Visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy.

27 Jun 2011

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Dr Seizaburo Kashiwagi presented the preliminary data from an influenza Phase III prophylaxis study conducted during the 2009/2010 pandemic flu season in Japan.

27 Jun 2011

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan.

24 Jun 2011

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

CEL-SCI Corporation announced today data from its Phase II clinical studies which showed that its lead drug Multikine was able to lower cholesterol in studies involving 120 head and neck cancer patients.

22 Jun 2011

NanoViricides plans to lease new cGMP manufacturing and lab space

NanoViricides, Inc. announced today that it will be leasing new space for cGMP production of its nanoviricides drug candidates against various viral diseases.

20 Jun 2011